DecisionPoint Financial’s Moderna MRNA Stock Holding History

DecisionPoint Financial’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-31	Closed	-$879	–	667
2025 Q1	$879	Hold	31	–	–	﹤0.01%	226
2024 Q4	$1.29K	Buy	+31	New	+$1.48K	﹤0.01%	231

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DecisionPoint Financial's MRNA Position: Q2 2025 in Review

DecisionPoint Financial sold out of Moderna (MRNA) in Q2 2025, closing a stake of 31 shares — an estimated $879 sold.

DecisionPoint Financial first reported a position in MRNA in Q4 2024 and held it in 2 quarters. The position peaked at $1.29K in Q4 2024. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

DecisionPoint Financial reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
DecisionPoint Financial sold 31 Moderna shares in Q2 2025, an estimated $879.
DecisionPoint Financial first reported a position in Moderna in Q4 2024 and held it in 2 quarters.
DecisionPoint Financial's Moderna position peaked at $1.29K in Q4 2024.
674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on DecisionPoint Financial's 13F filing for Q2 2025, filed 14 Aug 2025.